Akèy › Leksemi mieloïd egi › New York › Buffalo
Etid klinik pou Leksemi mieloïd egi nan Buffalo, NY
19 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Buffalo (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Roswell Park Comprehensive Cancer Center, Buffalo
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Roswell Park Cancer Institute, Buffalo
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Roswell Park Cancer Institute, Buffalo
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- State University of New York at Buffalo, Buffalo
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Roswell Park Comprehensive Cancer Center, Buffalo
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Roswell Park Cancer Institute, Buffalo
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Roswell Park Comprehensive Cancer Center, Buffalo
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 1
- Roswell Park Cancer Institute, Buffalo
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Roswell Park Cancer Institute, Buffalo
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Buffalo
- Kansè Poumon ki pa ti selil19 etid
- Kansè (tout kalite)19 etid
- Kansè poumon16 etid
- Kansè nan tete16 etid
- Kansè ovè13 etid
- Kansè Metastatik11 etid
- Kansè pwostat11 etid
- Melanom10 etid
- Myelom Miltip10 etid
- Obèsite9 etid
- Limfòm Burkitt8 etid
- Sendwòm myelodisplastik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.